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Abstract
Sirolimus is one of the most successful immunosuppressant drugs available but it
has an extremely low solubility in water that dramatically limits its oral bioavailability to
approximately 20%. This study is aimed to increase solubility of Sirolimus in aqueous
solutions through complexation with a metal ion. Using computer modeling and UV
absorbance spectroscopy, it was demonstrated that 1) Sirolimus interacts with Al3+, Cu2+,
Fe H, M n'+, Zn2+; 2) this interaction decreases UV light absorbance of Sirolimus
measured at X=280 nm; 3) a previously reported value of solubility of Sirolimus in water
is underestimated; 4) Sirolimus can exist in aqueous solutions in different soluble
physical forms, including multimers; 5) complexation of Sirolimus with Al3+ increases its
aqueous solubility that potentially can improve its oral bioavailability. Similar approach,
i.e. complexation with a metal ion, can be used to increase aqueous solubility of other
compounds containing ligands with unshared electron pairs, for example, cyclic
macrolides like Tacrolimus, derivatives of Tacrolimus and Sirolimus, as well as peptide
drugs such as Cyclosporin A.
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Introduction
Goal
To improve the aqueous solubility of Sirolimus through construction of a drugmetal ion complex.

History of Sirolimus
Organ transplantation is a life saving medical procedure worldwide. However, the
procedure does have its drawbacks, mainly being the insufficient quantity of donor
organs and organ rejection. As of May 2013, approximately 128,000 patients in the
United States were on the waiting list for organ transplantation, and actual
transplantations that where performed in 2012, were approximately 28,000 (Organ
Procurement and Transplantation Network (OPTN), 2013. OPTN: View data reports).
Once the organ is transplanted, the recipient's immune system identifies the foreign
antigens of the donor organ and rejects the organ essentially destroying the organ. In
order to avoid graft rejection, both donor and recipient are matched as closely as possible
in regards to their antigens[l]. Recipients are still required to be placed on a lifelong
regiment of immunosuppressive drugs.
Sirolimus (Rapamune, Rapamycin) (Fig. 1A) is an example of a successful
immunosuppressive drug that is prescribed post kidney transplantation. Sirolimus was
first isolated from a soil sample obtained from Easter Island in 1975[2]. Sirolimus is
produced by the bacterium Streptomyces hygroscopicus and its initial properties were
identified as having antimicrobial activity[3]. The progression of Sirolimus initial
discovery to the approval usage as an immunosuppressive drug took approximately 26
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years (Fig. 2). Later research demonstrated that the drug also had immunosuppressive
properties and in 1999 Sirolimus was approved by the U.S. FDA as an
immunosuppressive drug that could be prescribed for the prevention of rejection in renal
transplant patients[3].
Sirolimus is also used in medical devices, such as the Cypher stent, which is used
for the expansion of blocked coronary arteries preventing restenosis. Sirolimus is
gradually released within the artery wall and lowers the amount of normal cell growth in
order to prevent re-blockage of the artery (U.S. Food and Drug Administration (FDAT
2012. FDA: Medical devices. CYPHER™ Sirolimus-elutinz Coronary Stent - PO20026).

Mechanism of action (MOA)
The mechanism of action (MOA) of Sirolimus differs from its counterparts,
Cyclosporine (Fig. IB) and Tacrolimus (Fig. 1C). The ability of T-cells to recognize
proteins located on the antigen-presenting cell allows for cellular signaling to take place
via the T-cell receptor, which activates the calcineurin phosphate that dephosphorylates
the nuclear factor of activated T-cells (NFAT). The dephosphorylation of NFAT allows it
to enter the nucleus and act as a transcription factor, regulating Interleukin-2 (IL-2)
production. The regulation of IL-2 promotes T-cell activation and proliferation after the
interaction of the IL-2 receptor aided by the co-stimulatory signals of CD28[5].
Cyclosporine and Tacrolimus both inhibit the calcineurin phosphate by binding
with their corresponding protein resulting in a complex formation. The formation of the
drug complex allows for calcineurin to be inhibited and stops IL-2 production that stops
T-cell activation. Sirolimus does bind to its corresponding immunophilin in the same
manner as Cyclosporine and Tacrolimus (Fig 3); however, the MOA is distinct for
8

Sirolimus. Once bound to its binding protein, Sirolimus binds to the mammalian target of
Rapamycin (mTOR) complex of T-cells. This binding results in the disruption of the IL-2
receptor and inhibits T-cell proliferation by cell cycle arrest[5].
In addition, Sirolimus has been shown in recent research to have the ability to
promote autophagy in mice that have suffered spinal cord injury[4]. The study indicates
that the reason for autophagy promotion has to do with the inhibition of mTOR, which, in
return, allows for a higher concentration of the autophagy proteins LC3 and Beclin 1 in
the injured spinal cord of the mice[4].

Solubility of Sirolimus
Sirolimus has a molecular formula C51H79NO13 (molecular weight 914.2), is a
cyclic macrolide, does not have ionizable groups, is freely soluble in DMSO, and has a
low solubility in aqueous solutions that dramatically limits its bioavailability to
approximately 20%[6]. According to the Product Information from Product Number
R0395 (Sigma-Aldrich), Sirolimus is soluble in DMSO at 25 mg/mL (27.3 mM) with
reference to Sigma-Aldrich Production/Quality Control (Reference 2 in the Product
Information sheet). The Product Information sheet states that Sirolimus is “substantially
insoluble in water” with reference to The Merck Index. Monograph 8114 of The Merck
Index 14lh makes the only statement about solubility of Sirolimus in water: “Substantially
insol in water". Studies on solubility of Sirolimus in water report values of 2.6 pg/mL
(2.8 pM)[6].

Cost of Sirolimus
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In addition to Sirolimus having a low bioavailability that is caused by its low
solubility in aqueous solutions, it also is an expensive drug treatment for patients. An
annual treatment of Sirolimus cost approximately US $7,000.00 for patients who have
had kidney transplantations[7]. This study is aimed to increase solubility of Sirolimus in
aqueous solutions through the complexation of charged metal ions in order to potentially
increase its bioavailability.

Complexation with metal ions changes drug properties
Metal complexation is known to affect drug properties. Thus, Cu(II) and Zn(II)
significantly improve the antimicrobial activity of cephalexin[8], bacitracin is formulated
together with Zinc due to its higher stability (Merck Index, 14th, Monograph Number
936). As a free acid, aceglutamide is a nootropic drug, and in complex with aluminum it
is used as an antiulcerative (The Merck Index 14th, Monograph 25). Aloxiprin, a complex
of aspirin and aluminum, has better pharmacokinetic properties at acidic pH than aspirin
(The Merck Index 14th, Monograph 309). On the other hand, the antimicrobial activity of
1,4-naphthoquinones was decreased by metal complexation[9], tetracyclines lose their
antimicrobial activity when coordinated with metals[10], Mg2+ complexed with
fluoroquinolones results in a decrease in oral bioavailability[ll], metal complexation of
the fluoroquinolone norfloxacin decreases oral bioavailability of this antimicrobial
agent[12].

Hypothesis: “Complexation of Sirolimus with a metal ion can result in a charged
complex and thus increase its water solubility”
The use of certain immunosuppressive drugs, for example cyclosporines,
Tacrolimus and Sirolimus and their derivatives, is hampered by their low aqueous
10

solubility, and thus, low bioavailability. The same applies to drugs like Cyclosporin A
(CsA) (Fig. IB), which is a peptide. With different biosynthesis and not chemically
related to Tacrolimus (Fig. 1C) and Sirolimus (Fig. 1A), which are macrocyclic lactones,
CsA has one striking similarity among to them: the presence of 11 carbonyl and one
hydroxyl oxygens in CsA (Fig. IB), 4 carbonyl, 3 hydroxyl, 3 methoxyl, 1 lactone, and 1
epoxy oxygens in Tacrolimus (Fig. 1C), and 5 carbonyl, 3 hydroxyl, 3 methoxyl, 1
lactone, and 1 epoxy oxygens shown here in Sirolimus (Fig. 1A). These oxygens are
strong Lewis bases and form donor-acceptor bonds with metal ions, especially d-metal
ions, the interaction being stronger when the number of dents increases and the ligand has
the cyclic chemical structure. Thus, if the above-mentioned compounds, their analogs and
derivatives, would be able to bind metal ions, these drug-metal complexes should have
increased solubility in water.
In order to improve the aqueous solubility of Sirolimus, it might be possible to
form a stable complex of Sirolimus with a metal ion. The complexation of Sirolimus with
a charged metal ion would result in a charged complex and consequently increase its
water solubility, and improved water solubility of Sirolimus may lead to an improvement
of its bioavailability.

A choice of metal ions
The first candidates considered were Fe3+ and Al3+ ions since they are strong
Lewis acids and interact with such hard Lewis base as oxygen, and, importantly, have
lower toxicity than other high charged metal ions. Though Fe3+ is a stronger acid than
Al3+, Al3+ is a better candidate to start with since Fe3+ ion intensely absorbs in that UV
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part of the spectrum where Sirolimus can be detected by its absorbance, and Al3+ has a
smaller atom, which may fit better in the central pore of Sirolimus.
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Materials and Methods
Computer Modeling of Sirolimus with metal ions
ChemBio3D Ultra 12.0 software (CambridgeSoft Corporation, Cambridge, MA)
was used to model Sirolimus-metal ion interaction. MMFF94 algorithm was used to
minimize energy.

Preparation of Sirolimus
1 mg of Sirolimus (Sigma-Aldrich R0395) was diluted in 0.109 mL of freshly
opened DMSO (Sigma-Aldrich D2650) to make final concentration of 10 mM, aliquoted
by 5 pL aliquots and stored at -20°C. Using a precise Hamilton syringe, 1 pL of the 10
mM stock was dissolved in 1 mL of solvent or buffer to make 10 pM of the final
concentration of Sirolimus for spectrophotometric measurements. For all experiments
18.2 M il water (Milli-Q, Millipore) was used. All chemicals were purchased from
Sigma-Aldrich Co.

Absorbance measurements
Spectra of Sirolimus were measured with a Nanodrop ND-1000
spectrophotometer. Absorbance of Sirolimus at particular wavelengths was obtained from
the spectrum measured with the Nanodrop ND-1000 spectrophotometer. Additionally,
absorbance of Sirolimus at X=280 nm was measured in a quartz cuvette with the
spectrophotometer attachment of the Hitachi F-7000 spectrofluorometer. All absorbance
units are reported for 1.0 cm light path unless noted otherwise. All measurements were
done at room temperature. The advantage of using a spectrofluorometer in the
transmission mode is that both the incident light and transmitted light passes through
13

their own monochromators that avoids the fluorescence artifact if substances under
investigation are fluorescent. The incident light monochromator was set to ^=280 nm
with 5 nm slit, and the transmitted light monochromator was set to ^=280 nm with 20 nm
slit. The PMT voltage was set to 400 V.

Preparation of Sirolimus-Al3+ (SirAl) complex
1 pL of 10 mM Sirolimus in DMSO was mixed with 2 pL of 100 mM AICI3
solution in ethanol and evaporated in an Eppendorf Vacufuge vacuum centrifuge at 30°C
for 15 min. The pellet was reconstituted in buffer containing KC1 (150 mM), HEPES (10
mM), and pH=7.0 (NaOH) to model the intracellular ionic environment and precipitate
excess of free Al3+ as Al(OH)3. For control, the second sample was prepared with 2 pL of
ethanol and no AICI3. The samples were centrifuged for 1 min with a Mini Centrifuge to
sediment Al(OH)3 and other insoluble matter, and the supernatant was analyzed with the
Nanodrop ND-1000 spectrophotometer. The spectra were taken in 4-6 replicas in each
independent trial and averaged.
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Results
Computer Modeling of Sirolimus with metal ions
Energy minimization of free Sirolimus with MMFF94 algorithm revealed a
central pore (Fig. 4A). One generic dipositive metal ion (M2+) was manually placed next
to the structure of Sirolimus and minimization was done thereafter. The procedure was
repeated several times when M2+ was placed at different location next to Sirolimus. The
attempts to minimize energy with one M2+ ion starting from different locations
surprisingly revealed two different binding sites, the first of which is at two carbonyl
oxygens at C26 and C32 and one hydroxyl oxygen at C28 (Fig. 1A & 4B). Upon M2+
binding at this site, the molecule of Sirolimus did not change significantly its maximum
linear dimension and the central pore opened even further (Fig. 4A and 4B, planar
views). The second binding site was found at three carbonyl oxygens at C8, C9, C26, one
hydroxyl oxygen at C28, and one methoxyl oxygen at C27 (Fig. 1A & 4C). Upon M2+
binding at this site, the molecule of Sirolimus decreased its maximum linear dimension
and the central pore closed. For the first binding site, energy minimization resulted in a
decrease from 255.9 kcal/mol to 100.6 kcal/mol, and at the second binding site that
resulted in a decrease from 255.9 kcal/mol to 99.2 kcal/mol. It is important that modeling
predicts two different interactions resulting in either no change in the maximum linear
dimension (Fig. 4B) that should not significantly change light absorbance, or a decrease
in the maximum linear dimension that can potentially decrease light absorbance (Fig.
4C). A second M2+ ion was added next to Sirolimus and minimization was done
thereafter. Modeling with two M2+ ions predicted no change in the maximum linear
dimension and even further opening of the pore in the center (Fig. 4A, 4D) probably due
15

to the electrostatic repulsion of positively charged M2+s (Fig. 4D), and energy
minimization resulted in a decrease from 255.9 kcal/mol to 155.6 kcal/mol. Introduction
of the third M2+ ion resulted in an unstable behavior of the algorithm but binding three
M2+s may also be possible.

Interaction of Sirolimus with metal ions
After addition of 100 pM of A1K(S04)2, the absorbance of 10 pM Sirolimus in
water decreased from 0.370±0.018 to 0.333±0.016 (n=10, p<0.001, paired t-test) (Fig.
5A, 5C). The absorbance of 100 pM of A1K(S04)2 was negligible (0.004±0.003, n=4)
(Fig. 5B, 5C). Fig. 5 also reports similar experiments with 100 pM of other selected
metal ions and EDTA. Control absorbances of 100 pM of corresponding metal ions and
EDTA were taken in separate experiments (Fig. 5B, 5C). Surprisingly, EDTA that was
also tested to chelate possible contaminating metals in Sirolimus caused a similar
decrease in absorbance (Sigma-Aldrich does not have information on trace metal analysis
of Sirolimus, R0395). All effects of metal ions and EDTA in Fig. 5 were significant
(P<0.05) and corrected for metal ion absorbances that were important only in a case of
Fe3+.

Dilution of Sirolimus
1 pL of 10 mM stock of Sirolimus was added to 1 mL of DMSO and quickly
mixed. Dilution of Sirolimus in DMSO from the initial concentration of 10 pM to 0 in
IpM steps results in a linear decrease of absorbance (Fig. 6A, squares). In four
experiments shown, R2 of the linear fit were 0.9997, 0.9998, 0.9999, and 0.9993 (Fig. 6A,
squares). Dilution of Sirolimus in water from the initial concentration of 10 pM to 0 in
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lpM steps resulted in non-linear curves with R2 values of 0.981, 0.986, 0.976, and 0.987
that indicated significant deviation from linearity (Fig. 6A, circles). Interestingly, that
between 10 pM and 5 pM, the water dilution curves were smoothly bending and
asymptotically approaching a linear region between 5 and 0 pM (R"=0.989, 0.997, 0.996,
and 0.995). Mean±SEM values of experiments in Fig. 6A are plotted in Fig. 6B. The line
in Fig. 6B represents the best linear fit of the points between 0 and 5 pM. Fig. 6C
summarizes R2 values for the linear fit of the indicted ranges of Sirolimus concentrations.

Dilution of Sirolimus in the presence of Alum
The dilution experiment repeated in water in the presence of 100 pM Alum (Fig.
6D, triangles) demonstrated that Al3+ ion significantly decreases absorbance of Sirolimus
compared to free Sirolimus in water (Fig. 6D, circles).

UV Spectrum of Sirolimus
Water solution of Sirolimus was prepared at 10 pM concentration in a 1 mL vial,
and its spectrum was immediately taken with the Nanodrop ND-1000 spectrophotometer
(Fig. 7A), and approximately 20 min later from the same vial (Fig. 7B). Absorbance
spectra of Sirolimus (10 pM) in water demonstrated that there was no loss of absorbance
at least for 20 min (Fig. 7).

SirAl
In the control group with no AICI3 (Fig. 8, No Al) there was only background
absorbance -0.016±0.021 (n=6), while with AICI3 (SirAl) the spectra were similar to the
ones of Sirolimus (Fig. 7) and absorbance was 0.468±0.039 (n=8), significantly different
of NoAl (P<0.001). Control experiments demonstrated that AICI3 alone did not contribute
17

significantly to absorbance (-0.002±0.006, n=3). The same approach was used to make
and detect Sirolimus-Fe3+ complex (Ferrolimus) but due to intense absorbance of Fe3+ ion
at À,=280 nm, the UV absorbance data are difficult to interpret, and Ferrolimus data are
not included in this manuscript.

18

Discussion
Computer Modeling of Sirolimus with metal ions
Computational modeling of Sirolimus with metal ions revealed the possibility of
two distinct conformational changes that could take place in Sirolimus upon metal ion
binding (Fig. 4B and 4C). Because the shape of Sirolimus changes upon metal ion
binding and absorbance is proportional to the longest linear dimension of a molecule, this
change can potentially affect light absorbance, a decrease in Fig. 4C case. Though energy
minimization is similar for states B and C with a small favor of state C in silico, in situ
state C is expected to be more favorable because, in this state, coordination to 5 oxygens
is predicted compared to only 3 oxygens in state B (Fig. 4).

Solubility of Sirolimus in water
Though it is reported that solubility of Sirolimus in water is limited to 2.6 pg/mL
(2.8 pM)[6], both the time scans of 10 pM of Sirolimus absorbance at A,=280 nm (Fig.
5A) and spectra of 10 pM of Sirolimus taken immediately after dilution and 20 min after
(Fig. 7) demonstrate that there is no loss of absorbance at least for 20 min. At 10 pM
concentration Sirolimus is soluble in water but may exist as Absorbance of Sirolimus in
the concentration range between 10 and 0 pM in DMSO follows Beer-Lambert law (Fig.
4A squares) suggesting that only one form of Sirolimus is likely to be present in DMSO,
most likely a monomer. In water, however, the linear part of the dilution curve falls in the
range up to 5 pM, a value that is as twice as higher than reported previously for the
solubility of Sirolimus in water obtained by the HPLC method[6]. At concentrations
higher than 5 pM the dilution curve is deviating from linearity that can be seen in no
change or a decrease in R2 values with increasing number of data points (Fig. 5). Taking
19

into account that there is no loss in absorbance of Sirolimus at 10 pM concentration (Fig.
6), we speculate that Sirolimus is soluble at 10 pM concentration in water, however at
this concentration it may form a mixture of monomers and multimers, while approaching
5 pM concentration the multimers dissociate and Sirolimus exists as a monomer.
Hypothetically, the hydrophobic chains between C17 and C25 (Fig. 1A) can interact
decreasing their surface of exposure to water, thereby increasing water solubility of the
dimer.

Interaction of Sirolimus with metal ions
There are several lines of evidence that Sirolimus interacts with metal ions. First,
computer modeling predicts this with a slight favor of a conformational change that
decreases light absorbance (Fig. 4C). Second, a significant decrease in absorbance was
detected upon binding of Al3+, Cu2+, Fe3+, Mn2+, Zn2+ (Fig. 5) that favors a transition
from either state A or state B, or their combination, to state C (Fig. 4C) but not D (Fig.
4D). Third, the dilution experiment with Al3+ (Fig. 6D) even further supports a decrease
of absorbance of Sirolimus in the presence of metal ions.

SirAI
In eight trials UV absorbance measurements of SirAI (two representative
experiments are shown in Fig.8) showed the signature UV profile of the Sirolimus peak
(Fig. 7), while in the control trials no significant absorbance was observed indicating that
SirAI has significantly higher aqueous solubility than Sirolimus. It is impossible at this
moment to tell what exact concentration of SirAI in water was. For reference, 10 pM of
Sirolimus added as 1 pL of 10 mM stock in DMSO to 1 mL of water without the
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centrifugation procedures used for making SirAl results in absorbance between 0.347 and
0.395 at ?i=280 nm (Fig. 5C). The confounding parameters here are that 5 pM is the edge
of Lambert-Beer range of Sirolimus in water (Fig. 6B), and Sirolimus decreases its
absorbance when in complex with Al3+ (Fig. 5A, 5C, 6D). It may seem confusing that in
control (NoAl, Fig. 8) no characteristic UV spectrum of Sirolimus was detected though
the target concentration of Sirolimus was 10 pM. in contrast, 10 pM of Sirolimus resulted
in absorbance in the range between 0.347 and 0.395 in Fig. 5A, 5C, 6B, and 7. The
difference was that dry Sirolimus was attempted to be solubilized in an aqueous solution
for NoAl control, while in the rest of the figures Sirolimus was solubilized in water from
10 mM stock in DMSO that served as a carrier and helped to solubilize Sirolimus in
water. This even further suggests that Al3+ serves as carrier for dilution of Sirolimus in
water. SirAl in water is more promising to partition in an aqueous phase compared to
Sirolimus carried by DMSO because Al3+ ion is highly charged compared to DMSO;
thus, SirAl can potentially can increase bioavailability of Sirolimus. It still remains a
question if bioavailability of SirAl and Ferrolimus is higher than that of Sirolimus, and if
the complexes retain immunosuppressive properties of Sirolimus.

Conclusions
By demonstrating that interaction of Sirolimus with a metal ion, Al3+ in particular,
increases its aqueous solubility, the original goal was achieved. Similar approach can be
used to improve aqueous solubility of compounds containing unshared electron pairs, for
example, cyclic macrolides like Tacrolimus, derivatives of Tacrolimus and Sirolimus, as
well as peptide drugs such as Cyclosporin A, to increase their solubility through
complexation with metal ions. It has also been demonstrated that 1) interaction with
21

metal ions decreases the size of Sirolimus and its absorbance, 2) a previously reported
value of solubility of Sirolimus in water is underestimated, 3) Sirolimus can exist in
aqueous solutions in different soluble physical forms, including multimers. A number of
questions, however, remain unanswered, such as the paradoxical effect of EDTA on
absorbance of Sirolimus, the analytical identification/quantification of SirAl and
Ferrolimus via UPLC, determination of the dissociation constants of Sirolimus with metal
ions. These questions will be the subject of further studies as well as testing the
bioavailability of SirAl and Ferrolimus, and in vitro experimentations using T-cells in
order to observe if SirAl and Ferrolimus retain the immunosuppressive properties of
Sirolimus.
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Figures
Figure IA. Structure o f Sir olimus.

ch
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Figure IB. Structure o f Cyclosporin A.
Top panel is shown as in the Merck index, 14th edition, Monograph 2752. Bottom panel
is shown as in PubChem (Substance ID 134339249).

M eLeu-M eVal— N— Ç — C — Abu-M eGly
H
MeLeu-D-Ala-Ala-Mel_eu-Val-MeLeu------Cyclosporin A
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Figure 1C. Structure o f Tacrolimus (FK-506).

Figure 2. History o f Rapamycin (adopted from [3]).
1973

Isolation from Easter Island soil sample and characterization of antimicrobial activity.

1974

Wyeth scientists observe that rapamycin is immunosupressive. It inhibits the development of
adjuvant arthritis and experimental allergic encephalities in rodents.

1975

Rapamycin is demonstrated to have antitumor activity.

1980

Elucidation of chemical structure as a macrocyclic lactone.

1988

Demonstration that rapamycin prevents allograft rejection in stringent animal models of orgar
transplantation.

1990

Preclinical work completed to support IND filing for rapamycin in transplantation.

1991

First IND submission for rapamycin intravenous formulation. Oral formulation follows soon
thereafter.

1994

First Phase II trial in de novo recipients of renal allografts in combination with cyclosporine.
Rapamycin tablet formulations are tested in human subjects.

1995

Phase II study in de novo recipients of renal allografts with rapamycin as the base therapy
without cyclosporin.

1996

Phase III randomized, controlled clinical trials are initiated in North America, Europe, and
Australia to achieve approval of rapamycin in combination with cyclosporine.

1997

Clinical program initiated in oncology based on extensive work in animal models, discussions
with National Cancer Institute, and support from new head of oncology at Wyeth.
Work is initiated with Cordis to develop a rapamycin-coated intracoronary stent based on
results in rodents and pigs showing prevention of restenosis with rapamycin.

1998

Randomized Phase III clinical trials for cyclosporine withdrawal are initiated. Fifty-five
studies of rapaymycin for prevention of renal allograft rejection are submitted to the US FDA
and the European Medicines Evaluation Agency 2 Weeks ahead of schedule.

1999

US FDA approves rapamycin in combination with cyclosporine and corticosteroids for
prevention of rejection in renal transplant recipients less than 2 months after unanimous vote
of FDA advisory committee.
NDA is submitted for approval of the 1-mg rapamycin tablet based on pharmacokinetic
studies and one large randomized controlled trial showing the equivalent clinical activity of
the tablet and liquid formulations.

2001

European CPMP on appeal approves rapamycin as maintenance therapy for patients in whom
cyclosporine can be eliminated.

2002

FDA device advisory committee votes unanimously to approve rapamycin coated stent for
prevention of restenosis in coronary angioplasty.
Response to FDA approvable letter for Rapamune Maintenance Regimen is submitted.
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Figure 3. Mechanism o f Action o f Cyclosporine, Sirolimus, and Tacrolimus
(adopted from Oxford Medical Journal, 2013).

Image Source: http://qjmed.oxfordjournals.Org/content/96/6/401/F2.large.jpg

Figure 4. C om puter sim ulation o f Sir olim us-M etal Ion interaction.
Carbons, hydrogens, oxygens, nitrogens, metal ions are colored grey, white, red, blue,
green, respectively.

P lanar views.

A

B

C

D
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Figure 5. Selected metal ions and EDTA decrease absorbance o f Sirolimus.

A.

B.

A. Absorbance o f Sir olimus+Metal Ion (a representative experiment).
Absorbance was measured with the Hitachi F-7000 in the time scanning mode.
After taking the blank measurement (Blank) containing 2 mL of water in a 1 cm quartz
cuvette, 2 pL of 10 mM Sirolimus in DMSO was added to the cuvette at approximately
60 seconds, and measured for about 20 seconds. Then, 2 pL of 100 mM A1K(S04)2 was
added at approximately 110 seconds and measured for about 20 seconds. Similar protocol
was used with CUSO4, Fe(N03)3, MnCE, ZnS04, and EDTA. In this experiment, the
Blank intensity was 511.2, 248.0 after addition of Sirolimus, and 267.0 after addition of
Alum. This corresponds to Sirolimus absorbance of lg(511.2/248.0)=0.314, and
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lg(511.2/267.0)=0.282 after addition of Alum, a decrease in 0.314-0.282=0.032
absorbance units. TI, transmission intensity.

B. Absorbance o f metal ions (a representative experiment).
Control experiment for A. Absorbance was measured with the Hitachi F-7000 in
the time scanning mode. After taking the blank measurement (Blank) containing 2 mL of
water in a 1 cm quartz cuvette, 2 pL of 100 mM A1K(S04)2 was added at approximately
90 seconds and measured for about 20 seconds. Similar protocol was used with CuSC^,
Fe(N03)3, MnCE, ZnSCC, and EDTA. In this experiment, the Blank intensity was 556.0,
and 552.0 after addition of Alum. This corresponds to Alum absorbance of
lg(556.0/552.0)=0.003. TI, transmission intensity.

C. Sum m ary Table.
The table summarizes the effects of other selected metal ions and EDTA on
absorbance of Sirolimus obtained similarly to the panel A (Sirolimus, Sirolimus+Metal)
and the panel B (Metal), n, number of experiments; SD, standard deviation; P, Student ttest p value. The last but one column shows the corrected changes resulted from
interaction of Sirolimus and metal ion.

M etal (M e a n ± S E M )

(S iro lim u s+ M eta l)(S iro lim u s)-(M e ta l)

0 .0 5 2

0 .0 0 4 ± 0 .0 0 3 (n = 4 )

-0 .0 4 1

0 .3 5 6

0 .0 2 2

-0 .0 0 3 ± 0 .0 0 1 (n = 4 )

-0 .0 2 9

0 .0 2 6

0 .5 7 8

0 .0 2 2

0 .2 1 9 ± 0 .0 1 1 (n = 9 )

-0 .0 3 7

0.021

0 .3 4 2

0 .0 2 5

-0 .0 0 2 ± 0 .0 0 1 (n = 4 )

-0 .0 2 6

S ir o lim u s+
M etal

n

SD

M etal

A lu m

10

0 .3 7 0

0 .0 5 7

0 .3 3 3

C uS04

4

0 .3 8 7

0 .0 3 2

F e (N O ,),

4

0 .3 9 5

M nC I2

4

0 .3 7 0

S iro lim u s

SD

J

<0.
<0
<0.
<0.
<0.
Z nS04

11

0 .3 4 7

0 .0 6 2

0 .3 1 4

0 .0 6 1

0 .0 0 2 ± 0 .0 0 3 (n = 4 )

-0 .0 3 5

4

0 .3 6 9

0 .0 6 7

0 .3 2 4

0 .0 6 3

-0 .0 0 1 ± 0 .0 0 1 (n = 4 )

-0 .0 4 5

<0
EDTA
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Figure 6. Dilution o f Sirolimus.

A b so rb an ce

A. Individual runs of Sirolimus absorbance in DMSO (squares), and water (circles).
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B. M eanslSEM of Sirolimus absorbance in the panel A.

Sirolimus (jjM)
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C. R2 o f the linear fit for indicated ranges o f Sirolimus concentrations.
Sirolimus (jliM)
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A b s o rb a n c e

D. Dilutions in DMSO (squares), water (circles), and in water in the presence o f Alum
(triangles).

S iro lim u s (|jM)
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Figure 7. UV spectra o f Sirolimus,
Note that the absorbance units in this figure is reported for the 1.0 mm light path, and
should be multiplied by 10 to be converted to the 1.0 cm light path.
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F igure 8. U V spectra o f Sirolim us-Alum inum com plex (SirAl).
Two representative experiments of eight are depicted.
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